Oyster Point Pharma to Present at the 37th Annual J.P. Morgan Healthcare Conference
PRINCETON, N.J.--(BUSINESS WIRE)--Jan 3, 2019--Oyster Point Pharma, Inc., a privately held clinical-stage pharmaceutical company with an initial focus on developing novel therapies for the treatment of Dry Eye Disease, today announced that Jeffrey Nau, M.M.S., Ph.D., President and CEO, is scheduled to present a corporate overview at the J.P. Morgan Healthcare Conference in San Francisco, California. The presentation will begin at 4:00 p.m. Pacific Time on Tuesday, January 8, 2019 at the Westin St. Francis.
About Oyster Point Pharma, Inc.
Oyster Point Pharma is a clinical-stage pharmaceutical company leveraging neuroscience to discover, develop, and commercialize novel therapies to treat diseases with high unmet needs. The company’s initial focus is to develop innovative therapeutics to treat the signs and symptoms of Dry Eye Disease by stimulating the trigeminal parasympathetic pathway to activate the glands and cells responsible for tear film production, known as the Lacrimal Functional Unit. Oyster Point is leveraging a class of molecules called nicotinic acetylcholine receptor (nAChR) agonists to bind receptors on the trigeminal nerve, accessible within the nose, to stimulate natural tear film production.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190103005092/en/
CONTACT: Media contact:
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA NEW JERSEY
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS OPTICAL PHARMACEUTICAL
SOURCE: Oyster Point Pharma, Inc.
Copyright Business Wire 2019.
PUB: 01/03/2019 09:00 AM/DISC: 01/03/2019 09:01 AM